Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpAMIL:ARBS -0.33%77 Interest Coverage is 943.00 as of Dec. 2025, which is 504% above its 10-year median of 156.00. GuruFocus rates MIL:ARBS with a GF Score™ of 77/100 and a GF Value™ of €2.91 (Fairly Valued). Among 376 Biotechnology companies, Arterra Bioscience SpA ranks better than 62.23% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Arterra Bioscience SpA's
Operating Income
for the
six
months ended in Dec. 2025 was €0.94 Mil. Arterra Bioscience SpA's Interest Expense for the
six
months ended in Dec. 2025 was €-0.00 Mil.
Arterra Bioscience SpA's interest coverage for the quarter that ended in Dec. 2025 was 943.00.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Arterra Bioscience SpA has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Arterra Bioscience SpA's Interest Coverage or its related term are showing as below:
MIL:ARBS'
s Interest Coverage Range Over the Past 10 Years
Min: 78.33 Med: 156 Max: 2034
Current: 2034
MIL:ARBS's Interest Coverage is ranked better than 62.23% of 376
companies
in the Biotechnology industry
Industry Median: 104.025
vs MIL:ARBS: 2034.00
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Arterra Bioscience SpA Interest Coverage Related Terms
Arterra Bioscience SpA Interest Coverage Historical Data
* Premium members only.
The historical data trend for Arterra Bioscience SpA's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MIL:ARBS vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arterra Bioscience SpA (MIL:ARBS) has a Interest Coverage of 943.00 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Arterra Bioscience SpA and its competitors. This is 504% above median its historical median of 156.00. Over the past decade, Arterra Bioscience SpA's Interest Coverage has ranged from 78.33 to 2,034.00. According to the industry distribution chart, Arterra Bioscience SpA ranks #142 out of 376 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Arterra Bioscience SpA's Interest Coverage too high?
Arterra Bioscience SpA's current Interest Coverage of 943.00 is 504% above median its 10-year median of 156.00. Over the past 10 years, this metric has ranged from a low of 78.33 to a high of 2,034.00. The Biotechnology industry median Interest Coverage is 104.03. Arterra Bioscience SpA's value of 943.00 is 806.5% above this industry median. Based on the distribution chart, Arterra Bioscience SpA ranks #142 out of 376 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #142 out of 376 companies for Interest Coverage. This puts Arterra Bioscience SpA in the upper half of its industry. The industry median Interest Coverage is 104.03. Arterra Bioscience SpA's value of 943.00 is 806.5% above this benchmark. Historically, Arterra Bioscience SpA's own Interest Coverage has ranged from 78.33 to 2,034.00 over the past decade. While the company's 10-year median is 156.00 vs. the industry median of 104.03, Arterra Bioscience SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arterra Bioscience SpA's current Interest Coverage of 943.00 is 806.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Arterra Bioscience SpA and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arterra Bioscience SpA's current Interest Coverage is 943.00, which is 504% above median its own 10-year median of 156.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current Interest Coverage is 943.00, which is 504% above median its 10-year median of 156.00 and 806.5% above the Biotechnology industry median of 104.03. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current Interest Coverage is 943.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
Interest Coverage: 943.00 (504% above median its 10-year median of 156.00)
GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
Industry Position: 806.5% above the Biotechnology median (#142 of 376)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score
Get the complete analysis for MIL:ARBS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
